Nath Bio-Genes (India) Limited (NATHBIOGEN)

Loading page…

Nath Bio-Genes (India) Limited (NATHBIOGEN) · mywealthgrid

About

Nath Bio-Genes operates in agricultural food products within Consumer Staples, with recent quarterly revenue of ₹322–328 Cr (Jun 2026) and market capitalization of ₹293 Cr. The company maintains a conservative balance sheet (D/E 0.2) and has paid consistent annual dividends since at least 2021. Current valuation stands at PE 8.01.

Face value: ₹10

Market cap

₹262 Cr

P/E

7.1×

P/B

0.4×

Dividend yield

1.5%

ROE

6.3%

ROCE

8.3%

Debt / equity

0.2

OPM

11.8%

EPS (TTM)

₹19.3

Book value

₹358.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Profit volatility is severe: OPM ranges 5.43–18.08% across recent quarters, and Mar 2026 posted near-zero profit on ₹51.59 Cr revenue. Understand what drives these swings and whether they reflect seasonality, competition, or cycle position.
ROE of 6.28% is weak, indicating poor capital efficiency. Assess whether this reflects a cyclical trough or structural constraints in the business model.
Stock has declined 10.67% over 1 year despite dividend payments. Verify whether this reflects genuine operational weakness, sector headwinds, or market mispricing.
Quarterly revenue swings from ₹39–44 Cr (Sep 2025) to ₹322–328 Cr (Jun 2026) suggest high dependence on seasonal or cyclical demand. Verify sustainability of recent peaks.

Generated analysis · source review pending

Growth drivers

Recent peak quarterly revenue of ₹322–328 Cr (Jun 2026) is strongest in recent data; verify whether this represents sustainable demand or seasonal strength.
Conservative leverage (D/E 0.2) provides balance-sheet capacity for growth investment or strategic action if opportunity emerges—assess capital allocation strategy.
Consistent dividend payouts (documented 2021–2025) signal stable cash generation that could be redirected to growth if management chooses.
OPM varies 5.43–18.08% across quarters (Sep 2025 peak at 18.08%); verify what operational factors drive high-margin quarters to assess replication potential and cost structure flexibility.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹137.7-3.2%1Y

Quick read

rule-based

Pros

No positive flags triggered.

Cons

−Low return on equity of 6.4% (3-yr avg)
−Low dividend payout of 10.4% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

54/100

Business quality: 29
Growth: 36
Valuation: 97

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Lt Foods LimitedLTFOODSLTFOODS	₹13,862 Cr	₹14,836 Cr	₹11,633 Cr	₹1,247 Cr	10.6%	₹640 Cr	5.7%	20.1%	14.9%	176
Krbl LimitedKRBLKRBL	₹8,604 Cr	₹8,774 Cr	₹6,009 Cr	₹992 Cr	14.8%	₹758 Cr	10.6%	15.5%	11.7%	323
Gujarat Ambuja Exports LimitedGAELGAEL	₹7,233 Cr	₹7,667 Cr	₹6,032 Cr	₹602 Cr	8.1%	₹416 Cr	5.3%	13.2%	9.7%	84
Trualt Bioenergy LimitedTRUALTTRUALT	₹3,812 Cr	₹5,458 Cr	₹2,051 Cr	₹381 Cr	16.8%	₹149 Cr	5.6%	10.8%	6.3%	170
Kaveri Seed Company LimitedKSCLKSCL	₹3,676 Cr	₹3,676 Cr	₹1,279 Cr	₹292 Cr	24.2%	₹250 Cr	21.2%	18.2%	18.2%	396
Amir Chand Jagdish Kumar (Exports) LimitedAEROPLANEAEROPLANE	₹2,156 Cr	₹2,914 Cr	₹2,287 Cr	₹225 Cr	9.9%	₹103 Cr	4.5%	24.1%	11.2%	253
Sanstar LimitedSANSTARSANSTAR	₹2,063 Cr	₹2,083 Cr	₹821 Cr	₹54 Cr	4.8%	₹44 Cr	4.4%	5.5%	5.1%	53
Grm Overseas LimitedGRMOVERGRMOVER	₹1,613 Cr	₹1,979 Cr	₹1,869 Cr	₹102 Cr	5.1%	₹77 Cr	4.2%	23.7%	14.5%	212
Chaman Lal Setia Exports LimitedCLSELCLSEL	₹1,401 Cr	₹1,484 Cr	₹1,478 Cr	₹171 Cr	10.9%	₹125 Cr	8%	19%	14.6%	197
Avt Natural Products LimitedAVTNPLAVTNPL	₹1,338 Cr	₹1,452 Cr	₹822 Cr	₹114 Cr	12.6%	₹84 Cr	9.1%	16.9%	12.2%	327
Gulshan Polyols LimitedGULPOLYGULPOLY	₹1,009 Cr	₹1,401 Cr	₹2,260 Cr	₹134 Cr	4.7%	₹43 Cr	1.2%	7.5%	4.1%	49
Regaal Resources LimitedREGAALREGAAL	₹883 Cr	₹1,493 Cr	₹1,090 Cr	₹133 Cr	11.2%	₹60 Cr	4.9%	15%	15.2%	50

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	278	301	333	365	445
COGS	9	135	134	136	202
Gross profit	270	167	199	229	244
	233	118	149	180	191
	37	49	50	50	52
OPM %	13.4%	16.2%	15%	13.7%	11.8%
Depreciation	3	3	3	4	4
Interest	11	10	9	10	16
	-87	1	4	5	14
Profit before tax	-63	36	42	41	46
Tax	4	1	2	2	5
Tax %	6.2%	3.2%	4.7%	4.9%	10.1%
	-67	35	40	39	42
PAT margin %	-24.2%	11.6%	11.9%	10.6%	9.4%
EPS (₹)	-35.6	18.4	21.3	20.1	21
EPS adjusted (₹)	-35.5	18.4	20.9	20.3	21.9
	—	10.9%	9.4%	9.9%	9.5%
Annual report	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	19	19	19	19	19	19
Reserves	594	523	554	591	625	661
Minority interest	—	—	—	0	0	0
	101	93	105	105	123	139
	75	105	114	165	259	278
Total equity & liabilities	790	739	793	880	1,026	1,097
	247	245	244	241	250	249
CWIP	—	—	0	0	0	0
Investments	5	5	5	15	6	6
	538	490	543	625	770	842
Total assets	790	739	793	880	1,026	1,097

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	17	38	70	18	-13
	-20	-3	-27	-4	3
	-22	-2	-5	-2	-4
Net cash flow	-25	34	38	11	-13
Free cash flow	16	36	62	10	-16
CFO / Operating profit %	45.9%	78.7%	141%	35.3%	-24%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	96.9%	55.3%	59.8%	62.9%	54.7%
EBITDA margin %	13.4%	16.2%	15%	13.7%	11.8%
EBIT margin %	12.3%	15.2%	14%	12.6%	10.9%
PAT margin %	-24.2%	11.6%	11.9%	10.6%	9.4%
Working capital
Receivable days	112	118	103	89	70
Inventory days	9,406	564	629	910	816
Payable days	1,826	75	118	214	238
NWC days	7,692	606	615	785	649
Leverage
Current ratio	2.41	2.41	2.18	1.89	1.97
Debt to EBITDA	2.5	2.16	2.12	2.46	2.64
Debt to equity	0.17	0.18	0.17	0.19	0.2
Interest coverage	3.4	4.6	5.2	4.8	3.5
Asset turnover	0.38	0.38	0.38	0.36	0.41
Return ratios
Return on assets %	-9.1%	4.4%	4.5%	3.8%	3.8%
Return on capital employed %	6.6%	8.3%	7.9%	7.9%	8.3%
Return on equity %	-12.4%	6.1%	6.5%	6%	6.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	45.6%	45.6%	45.6%	45.6%	45.6%	45.6%	45.6%	45.6%	45.6%	45.6%	45.6%	45.6%
	0.22%	0.32%	0.27%	0.22%	0.19%	0.19%	0.21%	0.42%	0.32%	0.31%	0.23%	0.27%
	4.37%	4.37%	4.37%	4.38%	4.37%	4.37%	3.94%	2.25%	0.76%	0.01%	0.01%	0.01%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	49.81%	49.71%	49.76%	49.8%	49.84%	49.84%	50.25%	51.73%	53.32%	54.08%	54.16%	54.12%
No. of shareholders	—	—	—	—	—	—	—	—	34,122	33,550	33,031	32,564

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Nath Bio-Genes (India) Limited. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

May 2026Transcript AI Summary PPTREC
Nov 2025Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

6

Final dividend11 Sept 2026 · ex-date₹2
Final dividend14 Aug 2025 · ex-date₹2
Final dividend9 Aug 2024 · ex-date₹2
Final dividend4 Jul 2023 · ex-date₹2
Dividend dividend23 Jun 2022 · ex-date₹2
Final dividend18 Aug 2021 · ex-date₹2

1

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

21 announcementsExport CSV

28 Sept 2026, 4:50 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

5 Sept 2026, 4:45 pmCorp. Action

Corporate Action-Board to consider Dividend

Dividend/AGM PDF

4 Sept 2026, 5:07 pmCorp. Action

Corporate Action-Board to consider Dividend

Dividend/AGM PDF

1 Sept 2026, 5:36 pmCorp. Action

Record Date

Record Date PDF

1 Sept 2026, 5:34 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

1 Sept 2026, 5:24 pmAGM/EGM

Intimation Of Annual General Meeting

AGM PDF

30 Jul 2026, 12:45 pmCompany Update

Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation PDF

29 Jul 2026, 4:16 pmResult

Financial Results As Of 30Th June 2026.

Financial Results PDF

Date	Category	Subject	Filing
28 Sept 2026, 4:50 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
5 Sept 2026, 4:45 pm	Corp. Action Dividend/AGM	Corporate Action-Board to consider Dividend	PDF

Loading announcements…

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	96.9%	55.3%	59.8%	62.9%	54.7%
EBITDA margin %	13.4%	16.2%	15%	13.7%	11.8%
EBIT margin %	12.3%	15.2%	14%	12.6%	10.9%
PAT margin %	-24.2%	11.6%	11.9%	10.6%	9.4%
Working capital
Receivable days	112	118	103	89	70
Inventory days	9,406	564	629	910	816
Payable days	1,826	75	118	214	238
NWC days	7,692	606	615	785	649
Leverage
Current ratio	2.41	2.41	2.18	1.89	1.97
Debt to EBITDA	2.5	2.16	2.12	2.46	2.64
Debt to equity	0.17	0.18	0.17	0.19	0.2
Interest coverage	3.4	4.6	5.2	4.8	3.5
Asset turnover	0.38	0.38	0.38	0.36	0.41
Return ratios
Return on assets %	-9.1%	4.4%	4.5%	3.8%	3.8%
Return on capital employed %	6.6%	8.3%	7.9%	7.9%	8.3%
Return on equity %	-12.4%	6.1%	6.5%	6%	6.1%

42 deals · 31 Aug 2021 – 19 Sept 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
19 Sept 2025	ADITYA BIRLA SUN LIFE MUTUAL FUND	Bulk	NSE	Sell	1,26,830	₹165.08	₹2.09 Cr
5 Mar 2025	BAKULESH TRAMBAKLAL SHAH	Bulk	BSE	Buy	1,68,000	₹152.50	₹2.56 Cr
5 Mar 2025	BAKULESH SHAH PRIVATE TRUST	Bulk	BSE	Sell	1,68,000	₹152.50	₹2.56 Cr
4 Jul 2024	ADROIT FINANCIAL SERVICES PVT LTD	Bulk	NSE	Sell	1,33,322	₹262.20	₹3.50 Cr
4 Jul 2024	ADROIT FINANCIAL SERVICES PVT LTD	Bulk	NSE	Buy	1,33,322	₹261.12	₹3.48 Cr
1 Jul 2024	JAINAM BROKING LIMITED	Bulk	NSE	Buy	1,11,376	₹245.86	₹2.74 Cr
1 Jul 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Sell	1,03,767	₹236.15	₹2.45 Cr
1 Jul 2024	GRAVITON RESEARCH CAPITAL LLP	Bulk	NSE	Buy	1,03,767	₹236.35	₹2.45 Cr
1 Jul 2024	JAINAM BROKING LIMITED	Bulk	NSE	Sell	6,775	₹247.38	₹0.17 Cr
21 Feb 2024	AGRI TECH INDIA LIMITED	Bulk	BSE	Sell	5,04,000	₹217.00	₹10.94 Cr

1–10 of 42

1 / 5

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Nath Bio-Genes (India) Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

6

1

Announcements

Not in the F&O segment

6

1

No fund holdings on record

Announcements

Annual reports

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Nath Bio-Genes (India) Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Dividends6

Board meetings1

Announcements

Ratio timeline

Not in the F&O segment

Dividends6

Board meetings1

Quarterly record

Bulk & block deals

Board and management

No fund holdings on record

Announcements

Annual reports

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

6

1

6

1